Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNTech SE's change in inventory for the quarter that ended in Jun. 2026 was $4 Mil. It means BioNTech SE's inventory
declined by $4 Mil
from Mar. 2026 to Jun. 2026 .
BioNTech SE's change in inventory for the fiscal year that ended in Dec. 2025 was $208 Mil. It means BioNTech SE's inventory
declined by $208 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioNTech SE's Days Inventory for the quarter that ended in Jun. 2026 was 96.31.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioNTech SE's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.95.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioNTech SE's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.97.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioNTech SE's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE Change In Inventory Related Terms
BioNTech SE Change In Inventory Historical Data
* Premium members only.
The historical data trend for BioNTech SE's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $154 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BNTX) has a Change In Inventory of $154 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for BioNTech SE and its competitors.
Is BioNTech SE's Change In Inventory too high?
BioNTech SE's current Change In Inventory is $154 Mil. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Change In Inventory compare to INSM and INCY?
BioNTech SE's Change In Inventory of $154 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for BioNTech SE and its competitors. BioNTech SE's current Change In Inventory is $154 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Fairly Valued. The stock's GF Value™ is $85.02, compared to a current price of $91.00 — trading 7% above its estimated fair value. The current Change In Inventory is $154 Mil. BioNTech SE's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For BioNTech SE (BNTX), the current Change In Inventory is $154 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BNTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of $91.00 is trading 7% above its estimated GF Value™ of $85.02.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BNTX:
Change In Inventory: $154 Mil
GF Value™: $85.02 vs. price of $91.00 (7% above fair value)
No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for BNTX
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTX has been successfully added to your 
